New Compound Sensitizes Cancer Cells to Chemotherapy
the Cancer Therapy Advisor take:
According to new results published in the journal Angewandte Chemie - International Edition, researchers from three German institutions have identified a novel class of chemical compounds that sensitize cancer cells to chemotherapeutic drugs.
Furthermore, they identified the target enzyme of these chemicals, thus opening the possibility of developing new drugs that target that enzyme. The compound from the class of chemicals the researchers identified stimulates the death of rapidly proliferating cells by chemotherapeutic drugs. The compound is non-toxic. By sensitizing cancer cells to chemotherapy, lower doses of chemotherapy can be used, which will in turn decrease toxicity and resistance.
The new class of compounds is called T8, which specifically sensitizes cancer cells to the drug etoposide. Protein disulfide isomerase (PDI) is the target protein that the researchers identified for novel agents to have a sensitizing effect. In addition, the researchers found that the effect on PDI is reversible and its effect is only observed when administered with a chemotherapeutic agent like etoposide.
The researchers also say that T8 is capable of sensitizing various types of cancer cells, including breast, leukemic, and pancreatic cancer cells. The researchers hope to test T8 in a variety of in-vivo animal models and determine whether PDI can be used as a drug target.
A novel class of chemical compounds that sensitize cancer cells to chemotherapeutic drugs.
Researchers of Ludwig-Maximilians-Universitaet (LMU) in Munich report that a new class of chemical compounds makes cancer cells more sensitive to chemotherapeutic drugs. They have also pinpointed the relevant target enzyme, thus identifying a new target for anti-tumor agents. Researchers led by LMU's Professor Angelika Vollmar and Professor Stephan Sieber of the Technische Universität München have identified a class of chemicals that represent a potential new weapon in the fight against malignant tumors.
The compound is itself non-toxic, but it stimulates the killing of rapidly dividing cells by chemotherapeutic drugs. This sensitizing effect means that the latter can be used in lower doses, which makes it less likely that the target cells will become resistant to their lethal effect. The work was carried out by an interdisciplinary collaboration made up of scientists from LMU, TUM and the Saarland University in Saarbrücken, and the results appear in the latest issue of the journal "Angewandte Chemie - International Edition".
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma